Parsons Capital Management Incri Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Parsons Capital Management Incri reduced its stake in AbbVie Inc by 2.27% during the most recent quarter end. The investment management company now holds a total of 80,029 shares of AbbVie Inc which is valued at $5,377,149 after selling 1,855 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.AbbVie Inc makes up approximately 0.71% of Parsons Capital Management Incri’s portfolio.

Other Hedge Funds, Including , Peak6 Investments sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 530 shares of ABBV which is valued $35,611.Hemenway Trust Co reduced its stake in ABBV by selling 84 shares or 0.28% in the most recent quarter. The Hedge Fund company now holds 30,011 shares of ABBV which is valued at $2,009,236. AbbVie Inc makes up approx 0.51% of Hemenway Trust Co’s portfolio.Simmons Bank boosted its stake in ABBV in the latest quarter, The investment management firm added 1,273 additional shares and now holds a total of 40,908 shares of AbbVie Inc which is valued at $2,723,246. AbbVie Inc makes up approx 0.30% of Simmons Bank’s portfolio.Concert Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 12,708 additional shares and now holds a total of 64,268 shares of AbbVie Inc which is valued at $4,256,470. AbbVie Inc makes up approx 0.56% of Concert Wealth Management’s portfolio.Marcus Capital reduced its stake in ABBV by selling 50 shares or 0.18% in the most recent quarter. The Hedge Fund company now holds 27,100 shares of ABBV which is valued at $1,718,411. AbbVie Inc makes up approx 1.72% of Marcus Capital’s portfolio.

AbbVie Inc opened for trading at $66.57 and hit $67.18 on the upside on Friday, eventually ending the session at $67.1, with a gain of 0.49% or 0.33 points. The heightened volatility saw the trading volume jump to 67,09,360 shares. Company has a market cap of $109,275 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *